ApollomicsAPLMW +43.88%31 Pretax Margin % is % as of Dec. 2025. GuruFocus rates APLMW with a GF Score™ of 31/100. The stock has 5 warning signs investors should review. Among 944 Biotechnology companies, Apollomics ranks worse than 53.81% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Apollomics's Pre-Tax Income for the
six
months ended in Dec. 2025 was $1.60 Mil. Apollomics's Revenue for the
six
months ended in Dec. 2025 was $0.00 Mil. Therefore, Apollomics's pretax margin for the quarter that ended in Dec. 2025 was %.
The historical rank and industry rank for Apollomics's Pretax Margin % or its related term are showing as below:
APLMW'
s Pretax Margin % Range Over the Past 10 Years
Min: -128.66 Med: -128.66 Max: -128.66
Current: -128.66
APLMW's Pretax Margin % is ranked worse than 53.81% of 944
companies
in the Biotechnology industry
Industry Median: -90.5
vs APLMW: -128.66
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Apollomics Pretax Margin % Related Terms
Apollomics Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Apollomics's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
APLMW vs HYPD, MGX, KALA: Pretax Margin % Comparison
For the Biotechnology subindustry, Apollomics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apollomics Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apollomics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Apollomics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apollomics (APLMW) has a Pretax Margin % of % as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Apollomics and its competitors. According to the industry distribution chart, Apollomics ranks #508 out of 944 companies in the Biotechnology industry, placing it in the top 53.8%.
Is Apollomics' Pretax Margin % too high?
Apollomics' current Pretax Margin % is %. Based on the distribution chart, Apollomics ranks #508 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Apollomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Apollomics' Pretax Margin % compare to HYPD and MGX?
According to the Biotechnology industry distribution chart, Apollomics ranks #508 out of 944 companies for Pretax Margin %. This places Apollomics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Apollomics and its competitors. Apollomics's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apollomics stock overvalued right now?
Apollomics (APLMW) has a current Pretax Margin % of %. The current Pretax Margin % is %. Apollomics' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Apollomics (APLMW), the current Pretax Margin % is % as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
31GF Score
Get the complete analysis for APLMW
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APLMW has been successfully added to your 
